Lung Cancer Subtype Classification via Gene Expression Profiling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating lung cancer are inadequate due to the heterogeneity of lung tumors, leading to inaccurate classifications and ineffective therapies, with existing screening technologies producing false positives and limited impact on patient outcomes.
Innovation Solution
The development of methods and compositions that utilize gene expression profiling to classify lung cancer into specific subtypes, including the use of PCR and antibody-based detection techniques to identify biomarkers, allowing for more accurate diagnosis and prediction of therapeutic responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If high-resolution CT screening is used to detect lung tumors early, then detection sensitivity is improved, but false positive rate increases and does not change patient outcome
Solution Approach 1:
The invention segments lung cancer diagnosis into multiple molecular subtypes based on gene expression profiles. By dividing the heterogeneous lung cancer population into distinct molecular categories (such as squamous cell carcinoma, adenocarcinoma, and other subtypes with specific gene signatures), the method enables more precise classification beyond traditional histological typing, thereby improving diagnostic accuracy and reducing misclassification errors that lead to false positives.
Solution Approach 2:
The invention changes the diagnostic parameters from traditional imaging-based detection to molecular gene expression profiling. By measuring specific gene expression levels (such as CK5/6, TTF-1, Napsin A, and other marker genes) instead of relying solely on CT imaging characteristics, the method provides more reliable tumor characterization and subtype classification, improving both detection accuracy and outcome prediction.
2Ease of operation
If traditional histological classification is used for lung cancer, then diagnostic simplicity is maintained, but classification accuracy deteriorates due to tumor heterogeneity
Solution Approach 1:
The invention replaces traditional mechanical histological examination (microscopic visual inspection of tissue sections) with molecular biology-based gene expression analysis. By using PCR, RT-PCR, or other molecular techniques to detect and quantify specific gene transcripts, the method provides more accurate and objective tumor classification that overcomes the limitations of visual histological assessment, particularly for distinguishing between similar-looking tumor subtypes.
Solution Approach 2:
The invention introduces gene expression profiles as an intermediary layer between traditional histology and clinical diagnosis. By measuring the expression levels of specific marker genes (such as CK5/6 for squamous cell carcinoma, TTF-1 and Napsin A for adenocarcinoma), the method provides molecular evidence that complements and refines histological classification, enabling more accurate subtype determination while maintaining a systematic diagnostic approach.
3Ease of operation
If palliative therapy is used for advanced lung cancer, then symptom management is improved, but overall survival impact is limited to approximately 3 months
Solution Approach 1:
The invention performs preliminary molecular classification of lung cancer subtypes before initiating treatment. By identifying specific gene expression signatures and molecular markers early in the diagnostic process, the method enables selection of appropriate targeted therapies or clinical trials that are matched to the tumor's molecular characteristics, rather than relying solely on non-specific palliative chemotherapy. This preliminary molecular characterization can identify patients who may benefit from therapies with longer survival benefits.
Solution Approach 2:
The invention applies local quality by tailoring treatment approaches to specific molecular subtypes of lung cancer. Different gene expression profiles indicate different biological behaviors and treatment responses, so the method enables customization of therapy regimens based on the specific molecular characteristics of each patient's tumor, rather than applying uniform palliative therapy to all advanced lung cancer patients. This personalized approach can improve outcomes for specific subgroups.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise classification of lung cancer subtypes, improving diagnostic accuracy and therapeutic outcomes by distinguishing between normal and tumor samples, predicting chemotherapy responses, and tailoring treatment regimens based on tumor subtype.
Implementation Method 1
The methods include means for monitoring gene or biomarker expression including PCR and antibody-based detection
Implementation Method 2
immunocytochemistry techniques are provided that utilize antibodies to detect the expression of biomarker proteins in samples
Implementation Method 3
Expression can also be detected by nucleic acid-based techniques, including, for example, hybridization and RT-PCR
Data Source
AI summary
Compositions and methods useful in determining the major morphological types of lung cancer are provided. The methods include detecting expression of at least one gene or biomarker in a sample at the protein or nucleic level. The expression of the gene or biomarker can be indicative of the lung tumor subtype as well as prognostic and predictive for therapeutic response. The compositions and methods provided herein are suited for analysis of gene or biomarker expression at the protein or nucleic acid level in paraffin-embedded tissues.